Ligand Pharmaceuticals, Inc (NASDAQ: LGND)’s stock price has increased by 0.81% compared to its previous closing price of $113.66. However, the company has seen a -0.96% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-02 that The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Channel Therapeutics Corporation (“Channel”), merged with and into LNHC, Inc. (“LNHC”), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND), with LNHC surviving as a wholly owned subsidiary of Channel (the “Merger”).
Is It Worth Investing in Ligand Pharmaceuticals, Inc (NASDAQ: LGND) Right Now?
The 36-month beta value for LGND is also noteworthy at 0.88. There are mixed opinions on the stock, with 4 analysts rating it as a “buy”, 3 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for LGND is 18.80M, and at present, short sellers hold a 6.14% of that float. The average trading volume of LGND on July 04, 2025 was 122.81K shares.
LGND’s Market Performance
LGND’s stock has seen a -0.96% decrease for the week, with a 11.95% rise in the past month and a 5.38% gain in the past quarter. The volatility ratio for the week is 2.54%, and the volatility levels for the past 30 days are at 3.25% for Ligand Pharmaceuticals, Inc The simple moving average for the last 20 days is 1.18% for LGND stock, with a simple moving average of 3.68% for the last 200 days.
Analysts’ Opinion of LGND
Many brokerage firms have already submitted their reports for LGND stocks, with Stifel repeating the rating for LGND by listing it as a “Buy”. The predicted price for LGND in the upcoming period, according to Stifel is $143 based on the research report published on April 10, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see LGND reach a price target of $135. The rating they have provided for LGND stocks is “Outperform” according to the report published on October 03rd, 2024.
Stephens gave a rating of “Overweight” to LGND, setting the target price at $200 in the report published on April 14th of the previous year.
LGND Trading at 5.86% from the 50-Day Moving Average
After a stumble in the market that brought LGND to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.79% of loss for the given period.
Volatility was left at 3.25%, however, over the last 30 days, the volatility rate increased by 2.54%, as shares surge +10.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.62% upper at present.
During the last 5 trading sessions, LGND fell by -0.96%, which changed the moving average for the period of 200-days by +9.36% in comparison to the 20-day moving average, which settled at $113.25. In addition, Ligand Pharmaceuticals, Inc saw 35.04% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LGND starting from Reardon Andrew, who sold 500 shares at the price of $114.08 back on Jun 23 ’25. After this action, Reardon Andrew now owns 31,903 shares of Ligand Pharmaceuticals, Inc, valued at $57,042 using the latest closing price.
ANDREW THOMAS REARDON, the Officer of Ligand Pharmaceuticals, Inc, proposed sale 500 shares at $114.08 during a trade that took place back on Jun 23 ’25, which means that ANDREW THOMAS REARDON is holding N/A shares at $57,042 based on the most recent closing price.
Stock Fundamentals for LGND
Current profitability levels for the company are sitting at:
- -0.34% for the present operating margin
- 0.83% for the gross margin
The net margin for Ligand Pharmaceuticals, Inc stands at -0.73%. The total capital return value is set at -0.07%. Equity return is now at value -16.56%, with -14.58% for asset returns.
Based on Ligand Pharmaceuticals, Inc (LGND), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 11.87. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -16.44.
Currently, EBITDA for the company is 40.79 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 11.94. The receivables turnover for the company is 4.71for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.27.
Conclusion
In summary, Ligand Pharmaceuticals, Inc (LGND) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
